Literature DB >> 19480777

[Evaluation of cardiovascular risk in the cross-sectional phase of the Mediterranean Study].

V Gil-Guillén1, J Merino-Sánchez, T Sánchez-Ruiz, T Amorós-Barber, J Aznar-Vicente, J Abellán-Alemán, J L Llisterri-Caro, D Orozco-Beltrán.   

Abstract

INTRODUCTION AND
OBJECTIVES: The Mediterranean study quantifies high cardiovascular risk (HCR), consistency between REGICOR (R) and low risk SCORE (LS) scales, altered blood pressure (ABP) values in hypercholesterolemia (HC) without any history of hypertension (HT), high total cholesterol (HTC) values with HT with no background of HC and cardiac and renal damage in hypertensive patients. PATIENTS AND METHODS: A national, cross-sectional and multicenter study was performed with the participation of 751 physicians. The physicians individually evaluated 7,973 patients with HT and 5,319 with HC. HCR was defined as over 10% with R and 5% with LS. Intra-class correlation coefficient (ICC) and Pearson coefficient (r) were calculated. The percentages of ABP and HTC were quantified. Creatinine (cr) value, glomerular filtration rate using Cockroft-Gault (CG), and prevalence of left ventricular hypertrophy (LVH) were analyzed.
RESULTS: Regarding hypertensive patients: 17.3% HCR with R and 26.1% with LS. ICC = 0.222 (p < 0.0001), r = 0.61 (p < 0.0001), 64.7% HTC. There was no evaluation of LVH in 31.2% and a prevalence of 5.1%, prevalence of lesion and kidney failure (KF) of 4.7% and 1.6% respectively based on CR and 15.9% KF by CG. In HC patients, there was 21.1% of HCR with R and 21.5% with LS; ICC = 0.190 (p < 0.0001), r = 0.64 (p < 0.0001) and 33.7% ABP.
CONCLUSIONS: The SCORE scale identifies more patients with HCR than the REGICOR one in HT patients and a similar amount in HC patients. Consistency between both scales is poor. A significant ABP/HTC was found. In HT patients, the patients who were not evaluated for LVH and the percentage of KF are important.

Entities:  

Mesh:

Year:  2009        PMID: 19480777     DOI: 10.1016/s0014-2565(09)71237-8

Source DB:  PubMed          Journal:  Rev Clin Esp        ISSN: 0014-2565            Impact factor:   1.556


  4 in total

1.  [Non-compliance of dyslipaemic patients with electronic prescriptions].

Authors:  Esteban Ruiz García; Eva Román Cerdán; Emilio García-Jiménez; Fernando Martínez Martínez
Journal:  Aten Primaria       Date:  2010-03-20       Impact factor: 1.137

2.  Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia.

Authors:  Vicente Gil-Guillen; Domingo Orozco-Beltran; Josep Redon; Salvador Pita-Fernandez; Jorge Navarro-Pérez; Vicente Pallares; Francisco Valls; Carlos Fluixa; Antonio Fernandez; Jose M Martin-Moreno; Manuel Pascual-de-la-Torre; Jose L Trillo; Ramon Durazo-Arvizu; Richard Cooper; Marta Hermenegildo; Luis Rosado
Journal:  BMC Public Health       Date:  2010-11-22       Impact factor: 3.295

3.  Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial.

Authors:  Ignacio Párraga-Martínez; Joseba Rabanales-Sotos; Fernando Lago-Deibe; Juan M Téllez-Lapeira; Francisco Escobar-Rabadán; Alejandro Villena-Ferrer; Mariano Blasco-Valle; José M Ferreras-Amez; Susana Morena-Rayo; José M del Campo-del Campo; Maria Candelaria Ayuso-Raya; José J Pérez-Pascual
Journal:  BMC Cardiovasc Disord       Date:  2015-01-19       Impact factor: 2.298

4.  FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort.

Authors:  Rafael Azagra; Genís Roca; Gloria Encabo; Amada Aguyé; Marta Zwart; Sílvia Güell; Núria Puchol; Emili Gene; Enrique Casado; Pilar Sancho; Silvia Solà; Pere Torán; Milagros Iglesias; Maria Carmen Gisbert; Francesc López-Expósito; Jesús Pujol-Salud; Yolanda Fernandez-Hermida; Ana Puente; Mireia Rosàs; Vicente Bou; Juan José Antón; Gustavo Lansdberg; Juan Carlos Martín-Sánchez; Adolf Díez-Pérez; Daniel Prieto-Alhambra
Journal:  BMC Musculoskelet Disord       Date:  2012-10-22       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.